Volume 5, Issue 2 (Spring 2019)                   Iran J Neurosurg 2019, 5(2): 51-53 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Fatehi Hassanabad* M. Steroids use in glioblastoma: why do we persist?. Iran J Neurosurg. 2019; 5 (2) :51-53
URL: http://irjns.org/article-1-176-en.html
Corresponding authors address: Division of Neurosurgery, Vancouver General Hospital, Vancouver, Canada , fatehi@alumni.ubc.ca
Abstract:   (1166 Views)
 
Glioblastoma (GBM) is the most common malignant brain tumor and arises from glial cells. The condition was initially described ninety years ago; but, despite intense research efforts, the prognosis for most patients remains woefully poor. Over the past few decades, our understanding of the pathologic processes implicated in GBM have improved and we have a greater appreciation for the tumor-microenvironment interactions. We also have a much clearer perspective of the molecular genetics of the disease which will allow us to rationally develop new therapeutic strategies. However, an issue that remains somewhat overlooked is the significance of immune compromise in patients with GBM. Unfortunately, as surgeons and oncologists we continue to prescribe corticosteroids; a patently flawed therapeutic strategy.
Full Text [PDF 483 kb]   (279 Downloads) |   |   Full Text (HTML)  (300 Views)  
Type of Study: Letter to Editor |

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | Iranian Journal of Neurosurgery

Designed & Developed by : Yektaweb